PL422140A1 - Zastosowanie totarolu i kompozycja farmaceutyczna zawierająca totarol - Google Patents

Zastosowanie totarolu i kompozycja farmaceutyczna zawierająca totarol

Info

Publication number
PL422140A1
PL422140A1 PL422140A PL42214017A PL422140A1 PL 422140 A1 PL422140 A1 PL 422140A1 PL 422140 A PL422140 A PL 422140A PL 42214017 A PL42214017 A PL 42214017A PL 422140 A1 PL422140 A1 PL 422140A1
Authority
PL
Poland
Prior art keywords
totarol
application
treatment
parts
mass
Prior art date
Application number
PL422140A
Other languages
English (en)
Other versions
PL236429B1 (pl
Inventor
Mariusz CIĘCIARA
Artur Wrzosek
Original Assignee
Emergopharm Spółka Z Ograniczoną Odpowiedzialnością Spółka Komandytowa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergopharm Spółka Z Ograniczoną Odpowiedzialnością Spółka Komandytowa filed Critical Emergopharm Spółka Z Ograniczoną Odpowiedzialnością Spółka Komandytowa
Priority to PL422140A priority Critical patent/PL236429B1/pl
Priority to MA050980A priority patent/MA50980A/fr
Priority to RS20221013A priority patent/RS63728B1/sr
Priority to KR1020207003488A priority patent/KR20200024921A/ko
Priority to DK18765765.5T priority patent/DK3648751T3/da
Priority to US16/629,005 priority patent/US11534412B2/en
Priority to MA50979A priority patent/MA50979B1/fr
Priority to ES18765765T priority patent/ES2929646T3/es
Priority to EP18765765.5A priority patent/EP3648751B1/en
Priority to HUE18765765A priority patent/HUE060300T2/hu
Priority to SI201830794T priority patent/SI3648751T1/sl
Priority to CA3066602A priority patent/CA3066602C/en
Priority to PT187657655T priority patent/PT3648751T/pt
Priority to UAA201911771A priority patent/UA126031C2/uk
Priority to HRP20221338TT priority patent/HRP20221338T1/hr
Priority to RU2020104832A priority patent/RU2812223C2/ru
Priority to BR112019027839-7A priority patent/BR112019027839A2/pt
Priority to LTEPPCT/PL2018/000066T priority patent/LT3648751T/lt
Priority to PCT/PL2018/000066 priority patent/WO2019009739A1/en
Publication of PL422140A1 publication Critical patent/PL422140A1/pl
Priority to CL2019003720A priority patent/CL2019003720A1/es
Priority to IL271875A priority patent/IL271875B2/en
Publication of PL236429B1 publication Critical patent/PL236429B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Przedmiotem zgłoszenia jest zastosowanie totarolu do wytwarzania preparatu do leczenia stanów zapalnych błony śluzowej pochwy o podłożu bakteryjnym, do łagodzenia objawów w takim leczeniu oraz do profilaktyki i zapobiegania nawrotom takich stanów zapalnych. Zgłoszenie obejmuje także kompozycję farmaceutyczną do leczenia stanów zapalnych błony śluzowej pochwy o podłożu bakteryjnym, do łagodzenia objawów w takim leczeniu oraz do profilaktyki i zapobiegania nawrotom takich stanów zapalnych, zawierającą od 75 do 95 części masowych pochodnej celulozy, od 0,5 do 5 części masowych kwasu mlekowego, od 0,5 do 5 części masowych polimeru zasadowego, w której stosunek stechiometryczny kwasu mlekowego do polimeru zasadowego zawiera się w granicach od 1:1 do 8:1, i która zawiera totarol w ilości od 0,001 do 5 części masowych jako substancję aktywną.
PL422140A 2017-07-06 2017-07-06 Zastosowanie totarolu do wytwarzania preparatu do leczenia bakteryjnego zakażenia pochwy i kompozycja farmaceutyczna do zastosowania w leczeniu stanów zapalnych pochwy o podłożu bakteryjnym PL236429B1 (pl)

Priority Applications (21)

Application Number Priority Date Filing Date Title
PL422140A PL236429B1 (pl) 2017-07-06 2017-07-06 Zastosowanie totarolu do wytwarzania preparatu do leczenia bakteryjnego zakażenia pochwy i kompozycja farmaceutyczna do zastosowania w leczeniu stanów zapalnych pochwy o podłożu bakteryjnym
CA3066602A CA3066602C (en) 2017-07-06 2018-07-04 Application of totarol and pharmaceutical composition containing totarol
PT187657655T PT3648751T (pt) 2017-07-06 2018-07-04 Aplicação de totarol e composição farmacêutica contendo totarol
RS20221013A RS63728B1 (sr) 2017-07-06 2018-07-04 Primena totarola i farmaceutskog sastava koji sadrži totarol
DK18765765.5T DK3648751T3 (da) 2017-07-06 2018-07-04 Anvendelse af totarol og farmaceutisk sammensætning indeholdende totarol
US16/629,005 US11534412B2 (en) 2017-07-06 2018-07-04 Application of totarol and pharmaceutical composition containing totarol
MA50979A MA50979B1 (fr) 2017-07-06 2018-07-04 Application de totarol et composition pharmaceutique contenant du totarol
ES18765765T ES2929646T3 (es) 2017-07-06 2018-07-04 Aplicación de totarol y composición farmacéutica que contiene totarol
EP18765765.5A EP3648751B1 (en) 2017-07-06 2018-07-04 Application of totarol and pharmaceutical composition containing totarol
UAA201911771A UA126031C2 (uk) 2017-07-06 2018-07-04 Застосування тотаролу та фармацевтичної композиції, яка містить тотарол
SI201830794T SI3648751T1 (sl) 2017-07-06 2018-07-04 Uporaba totarola in farmacevtski sestavek, ki vsebuje totarol
MA050980A MA50980A (fr) 2017-07-06 2018-07-04 Application de totarol et composition pharmaceutique contenant du totarol
KR1020207003488A KR20200024921A (ko) 2017-07-06 2018-07-04 토타롤의 용도 및 토타롤을 함유하는 약제학적 조성물
HUE18765765A HUE060300T2 (hu) 2017-07-06 2018-07-04 Totarol alkalmazása és totarolt tartalmazó gyógyászati készítmény
HRP20221338TT HRP20221338T1 (hr) 2017-07-06 2018-07-04 Primjena totarola i farmaceutski pripravak koji sadrži totarol
RU2020104832A RU2812223C2 (ru) 2017-07-06 2018-07-04 Применение тотарола и фармацевтическая композиция, содержащая тотарол
BR112019027839-7A BR112019027839A2 (pt) 2017-07-06 2018-07-04 aplicação de totarol e composição farmacêutica contendo totarol
LTEPPCT/PL2018/000066T LT3648751T (lt) 2017-07-06 2018-07-04 Totarolio naudojimas, ir farmacinė kompozicija, kurios sudėtyje yra totarolio
PCT/PL2018/000066 WO2019009739A1 (en) 2017-07-06 2018-07-04 APPLICATION OF TOTAROL AND PHARMACEUTICAL COMPOSITION CONTAINING TOTAROL
CL2019003720A CL2019003720A1 (es) 2017-07-06 2019-12-18 Aplicación de totarol y composición farmacéutica que contiene totarol.
IL271875A IL271875B2 (en) 2017-07-06 2020-01-06 Preparations containing totarol and their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL422140A PL236429B1 (pl) 2017-07-06 2017-07-06 Zastosowanie totarolu do wytwarzania preparatu do leczenia bakteryjnego zakażenia pochwy i kompozycja farmaceutyczna do zastosowania w leczeniu stanów zapalnych pochwy o podłożu bakteryjnym

Publications (2)

Publication Number Publication Date
PL422140A1 true PL422140A1 (pl) 2019-01-14
PL236429B1 PL236429B1 (pl) 2021-01-11

Family

ID=63518002

Family Applications (1)

Application Number Title Priority Date Filing Date
PL422140A PL236429B1 (pl) 2017-07-06 2017-07-06 Zastosowanie totarolu do wytwarzania preparatu do leczenia bakteryjnego zakażenia pochwy i kompozycja farmaceutyczna do zastosowania w leczeniu stanów zapalnych pochwy o podłożu bakteryjnym

Country Status (19)

Country Link
US (1) US11534412B2 (pl)
EP (1) EP3648751B1 (pl)
KR (1) KR20200024921A (pl)
BR (1) BR112019027839A2 (pl)
CA (1) CA3066602C (pl)
CL (1) CL2019003720A1 (pl)
DK (1) DK3648751T3 (pl)
ES (1) ES2929646T3 (pl)
HR (1) HRP20221338T1 (pl)
HU (1) HUE060300T2 (pl)
IL (1) IL271875B2 (pl)
LT (1) LT3648751T (pl)
MA (2) MA50979B1 (pl)
PL (1) PL236429B1 (pl)
PT (1) PT3648751T (pl)
RS (1) RS63728B1 (pl)
SI (1) SI3648751T1 (pl)
UA (1) UA126031C2 (pl)
WO (1) WO2019009739A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114948891A (zh) * 2021-06-07 2022-08-30 南通联亚药业股份有限公司 药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2083809T3 (pl) * 2006-11-24 2014-09-30 Dsm Ip Assets Bv Kompozycja dietetyczna lub farmaceutyczna zawierająca tricykliczne diterpeny do leczenia depresji
RU2563208C1 (ru) * 2011-12-15 2015-09-20 Колгейт-Палмолив Компани Антибактериальная композиция, содержащая тимол и тотарол
CN106581687A (zh) * 2016-12-22 2017-04-26 吉林大学 以乳清蛋白为基质的桃柁酚抗菌纳米水凝胶及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL107491B1 (pl) 1977-10-29 1980-02-29 Przemyslowy Instytut Automatyk Czujnik dwustrunowy do pomiaru malych przesuniec
PL201869A1 (pl) 1977-10-29 1979-05-21 Inst Przemyslu Organiczego Sposob wytwarzania masy kablowej odpornej na dzialanie termitow
JP2700071B2 (ja) 1988-06-10 1998-01-19 株式会社資生堂 抗菌剤及びそれを用いた皮膚外用剤、口腔用組成物
PL166898B1 (pl) 1992-02-13 1995-06-30 Akad Medyczna Sposób wytwarzania kompleksu metylocelulozy z kwasem mlekowym
US6534548B1 (en) * 2001-10-02 2003-03-18 Kimberly-Clark Worldwide, Inc. Isoprenoid compositions for the inhibition of exoprotein production from gram positive bacteria
PL194437B1 (pl) 2002-06-05 2007-05-31 Akademia Medyczna Im Piastow S Sposób wytwarzania kompleksu na bazie kwasu mlekowego
NZ530834A (en) 2004-01-28 2007-06-29 Owen John Catchpole Near-critical extraction of totarol and/or a product containing totarol
US20090312279A1 (en) * 2005-12-23 2009-12-17 Sterilex Technologies, Llc Antimicrobial compositions
EP1925301A1 (en) * 2006-11-24 2008-05-28 DSMIP Assets B.V. Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders
JP5471335B2 (ja) 2009-11-17 2014-04-16 ライオン株式会社 口腔バイオフィルム殺菌剤
WO2014137231A2 (en) 2013-03-07 2014-09-12 T2G Biotechnology Limited Totarol extract formulations and uses thereof
DE102013108870A1 (de) * 2013-08-16 2015-02-19 Aimecs Gmbh Mittel zur Reinigung und zum Schutz von technischen Oberflächen
CN104027260A (zh) 2014-06-20 2014-09-10 广州薇美姿个人护理用品有限公司 一种含有桃柘酚的口腔护理用品
CN104688810A (zh) 2014-12-29 2015-06-10 昆明皕凯科技有限公司 一种基于天然植物原料的抗菌组合物及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2083809T3 (pl) * 2006-11-24 2014-09-30 Dsm Ip Assets Bv Kompozycja dietetyczna lub farmaceutyczna zawierająca tricykliczne diterpeny do leczenia depresji
RU2563208C1 (ru) * 2011-12-15 2015-09-20 Колгейт-Палмолив Компани Антибактериальная композиция, содержащая тимол и тотарол
CN106581687A (zh) * 2016-12-22 2017-04-26 吉林大学 以乳清蛋白为基质的桃柁酚抗菌纳米水凝胶及其制备方法

Also Published As

Publication number Publication date
PL236429B1 (pl) 2021-01-11
RS63728B1 (sr) 2022-12-30
RU2020104832A (ru) 2021-08-06
CA3066602A1 (en) 2019-01-10
KR20200024921A (ko) 2020-03-09
CA3066602C (en) 2024-01-02
HRP20221338T1 (hr) 2022-12-23
IL271875B2 (en) 2023-02-01
HUE060300T2 (hu) 2023-02-28
IL271875A (en) 2020-02-27
UA126031C2 (uk) 2022-08-03
IL271875B (en) 2022-10-01
ES2929646T3 (es) 2022-12-01
WO2019009739A1 (en) 2019-01-10
CL2019003720A1 (es) 2020-05-22
PT3648751T (pt) 2022-10-20
EP3648751B1 (en) 2022-09-28
DK3648751T3 (da) 2022-11-21
US20200289429A1 (en) 2020-09-17
RU2020104832A3 (pl) 2021-10-08
MA50979A (fr) 2020-10-14
MA50979B1 (fr) 2022-11-30
MA50980A (fr) 2020-10-14
BR112019027839A2 (pt) 2020-07-07
LT3648751T (lt) 2022-12-12
SI3648751T1 (sl) 2023-03-31
WO2019009739A4 (en) 2019-02-28
EP3648751A1 (en) 2020-05-13
US11534412B2 (en) 2022-12-27

Similar Documents

Publication Publication Date Title
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
WO2019199861A3 (en) Hemp extract for treatment of pain in animals
GB2551642A (en) Methods and compositions relating to microbial treatment and diagnosis of dis-orders
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2013003635A (es) Compuestos de n-heteroarilo.
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2022001144A (es) Metodos y composiciones para modular la microbiota intestinal y para manejar el peso.
PH12019550157A1 (en) Treatment for gingivitis
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
EP4410295A3 (en) Use of vibegron to treat overactive bladder
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
PL422140A1 (pl) Zastosowanie totarolu i kompozycja farmaceutyczna zawierająca totarol
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
MX2021003651A (es) Formulacion que comprende aceite ozonizado en el tratamiento de un tumor.
BR112015028302A2 (pt) formulação de pastilha de nicotina
BR112018070064A2 (pt) composições farmacêuticas estáveis para administração tópica e uso das mesmas
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
PL425327A1 (pl) Zastosowanie α,β,2',3'-tetrahydroksantohumolu
CO2021014253A2 (es) Formulación de tableta vaginal
MX2015013911A (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
MX2016006375A (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
MX2021000475A (es) Isoxazol como agonista del receptor fxr.
CY1124264T1 (el) Απο toy στοματος θεραπευτικος παραγοντας του θυρεοειδους